Abstracts tagged "race/ethnicity"

Abstract Number: 0106 • ACR Convergence 2022
A Systematic Review of Racial and Ethnic Disparities in Disease Related Outcomes Among Patients with SLE
Teresa Semalulu¹, Keerthana Pasumarthi¹, Kevin Zhao¹, Rauda AlDhaheri¹, Nadine Akbar², KAREN BEATTIE¹ and KONSTANTINOS TSELIOS³, ¹McMaster University, Hamilton, ON, Canada, ²Humber River Hospital and University of Toronto, Toronto, ON, Canada, ³McMaster University, Population Health Research Institute, Hamilton, ON, Canada
Background/Purpose: Racialized patients and ethnic minorities have worse outcomes in SLE. This is likely related to a complex interplay between genetic and non-genetic factors. Numerous…
Abstract Number: 0874 • ACR Convergence 2022
A Tale of Many Canadas: Associations of Ethnicity with Juvenile Idiopathic Arthritis Categories and Disease Severity at Presentation in a Multicultural Universal Healthcare Setting: Results from ReACCh-Out
Stephanie Wong¹, Lori Tucker², Kristin Houghton³, David Cabral⁴, Mercedes Chan², Ross Petty³, Andrea Human², Kimberly Morishita³, Rae Yeung⁵, Kiem Oen⁶, Ciaran Duffy⁷, Roberta Berard⁸, Gaelle Chedeville⁹, Thomas Loughin¹⁰, Matthew Berkowitz¹⁰ and Jaime Guzman¹¹, ¹University of British Columbia, Vancouver, BC, Canada, ²British Columbia Children's Hospital, Vancouver, BC, Canada, ³University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁴BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁵The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁶University of Manitoba, Toronto, ON, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸London Health Sciences Centre, London, ON, Canada, ⁹McGill University, Montréal, QC, Canada, ¹⁰Simon Fraser University, Vancouver, BC, Canada, ¹¹University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: The distribution of Juvenile Idiopathic Arthritis (JIA) categories and disease severity at presentation vary across countries, however it is unclear how much of this…
Abstract Number: 2045 • ACR Convergence 2022
Does Ancestry Influence Primary Sjögren’s Syndrome Phenotype or Severity?
Maxime Beydon¹, Marie Dulin², Raphaèle Seror³, Frederic Desmoulins², Xavier Mariette⁴ and Gaetane Nocturne⁵, ¹Université Paris Cité, Paris, France, ²Kremlin Bicêtre Hospital - APHP, Paris, France, ³University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, ⁴Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ⁵APHP, Le Kremlin Bicêtre, France
Background/Purpose: It is well established that in systemic lupus erythematous (SLE), disease burden is higher in patients from African ancestry (AA) than in Caucasian patients.…
Abstract Number: 0108 • ACR Convergence 2022
Study of the Level of Antibody Response to COVID-19 Vaccine in a Minority Population with Rheumatological Disorders
Tanushree Bhatt, Snigdha Gadireddy, Pravash Budhathoki and Giovanni Franchin, Bronxcare Health System, Bronx, NY
Background/Purpose: Multiple studies have shown reduced immunogenicity of mRNA covid vaccines in patients with rheumatological disease. The waning antibody levels in this population group, whether…
Abstract Number: 0962 • ACR Convergence 2022
Variability in Racial Disparities in Pregnancy Outcomes in Women with SLE by Diagnosis Algorithm
Megan Clowse¹, Jim Oates², Katie Kirchoff², April Barnado³, Saira Sheikh⁴, Leslie Crofford³ and Amanda Eudy⁵, ¹Duke University, Durham, NC, ²Medical University of South Carolina, Charleston, SC, ³Vanderbilt University Medical Center, Nashville, TN, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Duke University, Raleigh, NC
Background/Purpose: Disparities in pregnancy outcomes among women with SLE remain understudied, with few available racially-diverse datasets. We previously validated algorithms to identify pregnancies in women…
Abstract Number: 2060 • ACR Convergence 2022
Increased Risk of Adverse Renal Outcomes in Patients of African Ancestry with Systemic Lupus Erythematosus (SLE) – Role of APOL1
Gul Karakoc, Ge Liu, Jorge Gamboa, Cecilia Chung, Jonathan Mosley, Michael Stein and Vivian Kawai, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: SLE disproportionately affects individuals of African (AA) compared to European ancestry (EA). In addition to a higher incidence, the disease is more severe in…
Abstract Number: 0596 • ACR Convergence 2021
Racial Disparities in US Adults with Systemic Lupus Erythematosus: Prevalence, Quality of Life, Comorbidities and Healthcare Costs
Shannon Grabich¹, Cullen Seal², Robert Ortmann³ and Sandra Sze-jung Wu⁴, ¹Xcenda, Durham, NC, ²Xcenda, Carrollton, TX, ³AstraZeneca, Greenwood, IN, ⁴AstraZeneca, Wilmington, DE
Background/Purpose: SLE is a chronic, multisystem autoimmune disease characterized by reoccurring flares and remissions. It is more common among Asian, Black, and Hispanic populations. Racial…
Abstract Number: 1680 • ACR Convergence 2021
Impact of Race on the Efficacy and Safety of Tofacitinib in Patients with RA: A Post Hoc Analysis of Phase 2, 3, and 3b/4 Clinical Trials
Grace Wright¹, Eduardo Mysler², Yi-Hsing Chen³, Cassandra Kinch⁴, Arne Yndestad⁵, Kenneth Kwok⁶, Mary Jane Cadatal⁷, Rebecca Germino⁸ and Alexis Ogdie⁹, ¹Grace C Wright MD PC, and Association of Women in Rheumatology, New York, NY, ²Organización Médica de Investigación, Buenos Aires, Argentina, ³Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁴Pfizer Canada ULC, Kirkland, QC, Canada, ⁵Pfizer Inc, Oslo, Norway, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Manila, Philippines, ⁸Pfizer Inc, Groton, CT, ⁹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: While racial disparities in clinical outcomes for RA patients (pts) receiving bDMARDs or csDMARDs have been described,1 there remains a paucity of data on…
Abstract Number: 0598 • ACR Convergence 2021
Differences in Discoid Lupus Erythematosus Skin Lesion Distribution and Characteristics in Black and Non-Black Patients: A Retrospective Cohort Study
Adrienne Joseph, Brandon Windsor, Linda Hynan and Benjamin Chong, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Epidemiological studies have shown that discoid lupus erythematosus (DLE) has a higher incidence and prevalence in minorities, particularly Black individuals. Racial differences in clinical…
Abstract Number: 1726 • ACR Convergence 2021
A Pregnancy Planning Quality Score to Assess a Systematic Intervention to Improve Pregnancy Planning for Women with SLE
Catherine Sims¹, Amanda Eudy¹, Jayanth Doss¹, Lisa Criscione-Schreiber², Kai Sun², Rebecca Sadun¹, Jennifer Rogers² and Megan Clowse³, ¹Duke University, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Chapel Hill, NC
Background/Purpose: The safest pregnancies for women with SLE coincide with periods of disease quiescence maintained by pregnancy-compatible medications. In the US, Black women are more…
Abstract Number: 0601 • ACR Convergence 2021
Racial Differences in Medication Beliefs Among SLE Patients
D Ryan Anderson¹, Amanda Eudy², Megan Clowse³, Rebecca Sadun², Jennifer Rogers², Lisa Criscione-Schreiber⁴, Jayanth Doss², Corrine Volis⁵, Theresa Coles² and Kai Sun², ¹Duke University Hospital, Durham, NC, ²Duke University, Durham, NC, ³Duke University, Chapel Hill, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Medication adherence is essential to establishing and maintaining disease remission among SLE patients. Patients’ beliefs about treatment influence engagement and adherence to therapy. We…
Abstract Number: 1755 • ACR Convergence 2021
Increasing Participation of Underrepresented Groups in Lupus Clinical Trials: Insights from Qualitative Interviews with Patients and Physicians
Saira Sheikh¹, Maria Naylor², Becky Lane², Jennifer Sacks², Janine Gaiha-Rohrbach² and Cherie Butts², ¹University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ²Biogen, Cambridge, MA
Background/Purpose: Systemic lupus erythematosus disproportionately affects Black/African American (AA) and Latino/a populations.1 Challenges to engage and include these populations in clinical trials (CTs) can be…
Abstract Number: 0604 • ACR Convergence 2021
Disparities in Burden of Disease in Patients with RA Across Racial and Ethnic Groups
Jacqueline O’Brien¹, Sang Hee Park², Taylor Blachley¹, Maya Marchese¹, Nicole Middaugh¹, Xue Han², Keith Wittstock² and Leslie Harrold¹, ¹CorEvitas, LLC, Waltham, MA, ²Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Prior research has shown that differences exist in disease activity and clinical outcomes for RA across racial and ethnic groups in the US.1 This…
Abstract Number: 1780 • ACR Convergence 2021
Racial Disparities in Comorbidities of Patients with Psoriatic Arthritis
Sabahath Jaleel¹, Yael Ross¹ and Marina Magrey², ¹Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ²Case Western Reserve Universtiy at MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Racial heterogeneity of the US population makes it imperative to study the racial differences in clinical characteristics, medication use and co-morbidities of PsA patients…
Abstract Number: 0608 • ACR Convergence 2021
Adaptation of a Shared Decision-Making Tool for Early Rheumatoid Arthritis Treatment Decisions with Indigenous Patients
Valerie Umaefulam¹, Terri-Lynn Fox¹, Glen Hazlewood¹, Nick Bansback², Claire Barber¹ and Cheryl Barnabe¹, ¹University of Calgary, Calgary, AB, Canada, ²University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Patient decision aids (PtDA) can enable shared decision-making between patients and healthcare providers. We have previously developed a PtDA for first-line methotrexate-based treatment options…

« Previous Page
1
…
7
8
9
10
11
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].